A Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Ineligible Multiple Myeloma

We sought a regimen that incorporates optimal novel agents in transplant-ineligible patients that balances efficacy with toxicity. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population. RVD lite was administered over a 35-day cycle. Lenalidomide 15 mg was g...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Haematol
Asıl Yazarlar: O’Donnell, Elizabeth K., Laubach, Jacob P., Yee, Andrew J., Chen, Tianqi, Huff, Carol Ann, Basile, Frank G., Wade, Philip M., Paba-Prada, Claudia E., Ghobrial, Irene M., Schlossman, Robert L., Burke, Jill N., Harrington, Cynthia C., Lively, Kathleen J., Lyons, Hannah F., Munshi, Nikhil C., Anderson, Kenneth C., Trippa, Lorenzo, Richardson, Paul G., Raje, Noopur S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6074026/
https://ncbi.nlm.nih.gov/pubmed/29740809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15261
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller